Cited 1 times since 2023 (0.6 per year) source: EuropePMC JACC. Clinical electrophysiology, Volume 9, Issue 8 Pt 3, 24 4 2023, Pages 1719-1729 Risk of Adverse Outcomes Associated With Cardiac Sarcoidosis Diagnostic Schemes. Myadam R, Crawford TC, Bogun FM, Gu X, Ellenbogen KA, Jasti S, Chicos AB, Roukoz H, Zimetbaum PJ, Kalbfleisch SJ, Murgatroyd FD, Steckman DA, Rosenfeld LE, Garlitski AC, Soejima K, Bhan AK, Vedantham V, Dickfeld TL, De Lurgio DB, Platonov PG, Zipse MM, Nishiuchi S, Ortman ML, Narasimhan C, Patton KK, Rosenthal DG, Mukerji SS, Hoogendoorn JC, Zeppenfeld K, Sauer WH, Kron J, Cardiac Sarcoidosis Consortium
Background
Multiple cardiac sarcoidosis (CS) diagnostic schemes have been published.
Objectives
This study aims to evaluate the association of different CS diagnostic schemes with adverse outcomes. The diagnostic schemes evaluated were 1993, 2006, and 2017 Japanese criteria and the 2014 Heart Rhythm Society criteria.
Methods
Data were collected from the Cardiac Sarcoidosis Consortium, an international registry of CS patients. Outcome events were any of the following: all-cause mortality, left ventricular assist device placement, heart transplantation, and appropriate implantable cardioverter-defibrillator therapy. Logistic regression analysis evaluated the association of outcomes with each CS diagnostic scheme.
Results
A total of 587 subjects met the following criteria: 1993 Japanese (n = 310, 52.8%), 2006 Japanese (n = 312, 53.2%), 2014 Heart Rhythm Society (n = 480, 81.8%), and 2017 Japanese (n = 112, 19.1%). Patients who met the 1993 criteria were more likely to experience an event than patients who did not (n = 109 of 310, 35.2% vs n = 59 of 277, 21.3%; OR: 2.00; 95% CI: 1.38-2.90; P < 0.001). Similarly, patients who met the 2006 criteria were more likely to have an event than patients who did not (n = 116 of 312, 37.2% vs n = 52 of 275, 18.9%; OR: 2.54; 95% CI: 1.74-3.71; P < 0.001). There was no statistically significant association between the occurrence of an event and whether a patient met the 2014 or the 2017 criteria (OR: 1.39; 95% CI: 0.85-2.27; P = 0.18 or OR: 1.51; 95% CI: 0.97-2.33; P = 0.067, respectively).
Conclusions
CS patients who met the 1993 and the 2006 criteria had higher odds of adverse clinical outcomes. Future research is needed to prospectively evaluate existing diagnostic schemes and develop new risk models for this complex disease.
